Swara Baby Products, Upcoming IPO: Building Scale in India’s Hygiene Industry
Swara Baby Products Limited, India’s largest independent contract manufacturer in the disposable hygiene sector, is entering the public markets with a ₹1,000 Crore IPO. The issue is split evenly between a fresh issue of equity shares and an offer for sale by existing shareholders, including Brainbees Solutions (FirstCry). The Offer in Detail: Fresh Issue: ₹500 Crore and Offer for Sale: ₹500 Crore (₹300 Crore by Brainbees Solutions, ₹200 Crore by Anadya Bon Merchari LLP)
Use of Proceeds:
–> ₹198.2 Crore for a new manufacturing facility in Pithampur, Madhya Pradesh
–> ₹100 Crore for debt repayment
–> ₹27.5 Crore for subsidiary debt reduction
–> Balance for acquisitions and general corporate purposes
Business Snapshot:
Swara operates across baby care, adult incontinence, and feminine hygiene. It is the trusted white-label partner for leading brands like FirstCry, Piramal Pharma, and Himalaya Wellness, while also building its own consumer brands: Cuddles (baby care) and Shields (adult incontinence).
From a single diaper line in 2018, the company now runs 20 fully automated lines across four facilities in Madhya Pradesh. This scale makes it the largest contract manufacturer by value in India’s hygiene industry.
Competitive Advantages
• Scale: From one line in 2018 to 20 lines in 2026, enabling economies of scale.
• Location: Central India hub ensures efficient logistics across consumption markets.
• Integrated Offering: Capability across baby, adult, and feminine hygiene.
• Regulatory Edge: First BIS-certified diaper manufacturer in India, plus FDA, FSC, OEKO-TEX certifications.
• Innovation: Proprietary “Tree-Free” diaper technology reduces wood-based material by 93%.
• Automation: End-to-end automation ensures consistent quality and traceability.
Industry Dynamics
India’s hygiene market has evolved from negligible organized presence pre-2000s to mainstream adoption today. Global MNCs like P&G and Unicharm created awareness, but domestic players and private labels have steadily gained ground. The combined share of the top three MNCs fell from ~76% in FY20 to ~68% in FY25, as challenger brands and contract manufacturers expanded. Government incentives under the PLI scheme and stricter BIS standards are accelerating formalization.
Financial Performance
• Revenue: ₹1,164 Crore in FY26, up from ₹750 Crore in FY24 (24.6% CAGR).
• PAT: ₹95.6 Crore in FY26, nearly flat compared to FY24 despite higher sales.
• ROE: 20.1% in FY26, down from 34.5% in FY24.
• ROCE: 13.9% in FY26, down from 21.9% in FY24.
• Operating Cash Flow: ₹18.5 Crore in FY26, down from ₹61.4 Crore in FY25.
Risks to Monitor
• Customer Concentration: Top ten customers contribute 80% of revenue; FirstCry alone accounts for 22.6%.
• Debt Exposure: Borrowings exceed ₹470 Crore; debt-equity ratio at 0.81.
• Raw Material Dependence: 41% of purchases are imported, exposing Swara to global supply chain volatility.
• Execution Risk: Timely completion of the Pithampur project is critical.
The Bigger Picture
Swara Baby Products has transformed from a niche player into a sector leader with ambitions beyond India. Its strengths of scale, regulatory leadership, and promoter backing are undeniable. Yet, investors must weigh these against customer concentration, debt exposure, and execution risks. For those tracking India’s consumer hygiene story, this IPO is more than a fundraising event. It reflects how domestic manufacturers are scaling up, innovating, and positioning themselves against global incumbents in a market that is still expanding
Source: SEBI DRHP
Public Appearance Disclosures:
I, Surender Singh (Proprietor My Equity Sherpa), am a SEBI registered research analyst (INH000026035). I hereby disclose that:
a. Neither I, nor my family members, have any financial interest in the subject company at the time of this publication.
b. Neither I nor my family members or associates hold actual or beneficial ownership of one per cent. or more securities of the subject company, measured at the end of the month immediately preceding this disclosure.
c. Neither I nor my family members or associates have any other material conflict of interest relating to the subject company at the time of this publication.
d. Neither I nor my associates have received any compensation from the subject company in the past twelve months.
e. Furthermore, neither I nor my associates have received any compensation for investment banking, merchant banking, or brokerage services from the subject company in the past twelve months. I have also not received any compensation or other benefits from the subject company or a third party in connection with this analysis.
f. The company’s parent Brainbees Solutions (FirstCry) is under active coverage in our stock advisory for our paid subscribers.
